[ONTX] Onconova Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.39 Change: 0.03 (1.27%)
Ext. hours: Change: 0 (0%)

chart ONTX

Refresh chart

Strongest Trends Summary For ONTX

ONTX is in the medium-term down -67% in 2 years and down -87% in 2 years and down -93% in 2 years. In the long-term down -95% in 4 years and up 30069% in 23 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Its clinical-stage product candidates include rigosertib intravenous that is in Phase III trials for higher risk myelodysplastic syndromes (MDS); rigosertib Oral, which is Phase II clinical trials for patients with transfusion-dependent lower risk MDS and in patients with head and neck cancers; and a combination of rigosertib Oral and azacitidine in a Phase 1/2 study of first-line MDS patients. The company?s clinical-stage product candidates also comprise ON 013105, a small molecule targeting an important regulatory protein, cyclin D1, which is found at elevated levels in cancer cells; and recilisib, a molecule with radiation protection properties has completed four Phase I clinical trials. In addition, its preclinical products consist of ON 1231320, an inhibitor of polo-like kinase 2; ON 123300, an inhibitor of the cell cycle and cancer cell metabolism

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -8.8% Sales Growth - Q/Q0% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-156.2% ROE-487.72% ROI
Current Ratio3.38 Quick Ratio Long Term Debt/Equity Debt Ratio0.92
Gross Margin Operating Margin-12282.7% Net Profit Margin-12279.7% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities-9.85 M Gross Profit
Net Profit-12.34 M Operating Profit-12.35 M Total Assets36.71 M Total Current Assets36.35 M
Total Current Liabilities10.76 M Total Debt Total Liabilities24.95 M Total Revenue110 K
Technical Data
High 52 week5.78 Low 52 week0.3 Last close0.3 Last change-24.58%
RSI26.62 Average true range0.06 Beta0.13 Volume18.76 K
Simple moving average 20 days-37.42% Simple moving average 50 days-66.09% Simple moving average 200 days-88.69%
Performance Data
Performance Week-16.19% Performance Month-64.92% Performance Quart-86.53% Performance Half-90.77%
Performance Year-92.55% Performance Year-to-date-85.7% Volatility daily10.4% Volatility weekly23.26%
Volatility monthly47.67% Volatility yearly165.14% Relative Volume157.7% Average Volume426.28 K
New High New Low

News

2021-04-01 08:00:00 | Onconova Therapeutics Announces Enrollment in Second Cohort of Phase 1 Study with ON 123300 in China

2021-03-29 08:00:00 | Onconova to Present at the Spring 2021 Oncology Investor Conference

2021-03-11 16:05:00 | Onconova Therapeutics Reports Full Year 2020 Financial Results, Provides Business Update

2021-03-11 14:30:00 | Onconova Therapeutics, Inc. to Host Earnings Call

2021-03-04 16:15:00 | Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results

2021-03-01 08:00:00 | Onconova Therapeutics to Participate in Three Investment Conferences During the Month of March

2021-02-24 08:00:00 | Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

2021-02-22 09:47:21 | 5 Value Stocks In The Healthcare Sector

2021-02-17 17:51:00 | Why Onconova Therapeutics Stock Soared Today

2021-02-16 16:03:00 | Onconova Therapeutics, Inc. Announces Closing of $28.75 Million Public Offering of Common Stock Including Full Exercise of the Over-Allotment Option

2021-02-16 08:00:00 | Onconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference

2021-02-10 22:49:00 | Onconova Therapeutics, Inc. Announces Pricing of $25 Million Public Offering of Common Stock

2021-02-10 16:01:00 | Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

2021-02-04 11:54:52 | Return On Capital Employed Overview: Onconova Therapeutics

2021-01-25 09:49:21 | 5 Value Stocks In The Healthcare Sector

2021-01-14 08:00:00 | Onconova Therapeutics, Inc. to Present at NobleCon17 Virtual Event

2021-01-07 09:40:00 | Onconova Therapeutics, Inc. Announces $8.7 Million Public Offering

2020-12-21 08:00:00 | Onconova Therapeutics Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300

2020-12-01 10:27:09 | Return On Capital Employed Overview: Onconova Therapeutics

2020-11-23 08:00:00 | Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300

2020-11-12 16:05:00 | Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

2020-11-12 14:30:00 | Onconova Therapeutics, Inc. to Host Earnings Call

2020-11-05 08:00:00 | Onconova Therapeutics to Provide Corporate Update and Third Quarter 2020 Financial Results on November 12, 2020

2020-10-13 08:00:00 | Onconova Therapeutics to Present Update During the 2020 BIO Investor Forum Digital Event

2020-10-05 09:44:52 | 5 Value Stocks To Watch In The Healthcare Sector

2020-09-21 10:08:46 | Looking Into Onconova Therapeutics's Return On Capital Employed

2020-09-21 08:00:00 | Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals

2020-09-09 08:00:00 | Onconova Therapeutics Announces Participation at Upcoming Virtual Events

2020-08-31 08:41:12 | Overview Of Value Stocks In The Healthcare Sector

2020-08-31 08:00:00 | Onconova Therapeutics Announces Election of James J. Marino, JD, MBA as Chairman of the Board of Directors

2020-08-26 18:42:22 | After an Unfortunate Surprise, Can Onconova Bounce Back? Analyst Weighs In

2020-08-25 10:06:02 | Onconova's Cancer Study Fails to Meet Endpoint, Shares Down

2020-08-24 11:15:20 | Return On Capital Employed Overview: Onconova Therapeutics

2020-08-24 07:30:00 | Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial

2020-08-17 11:46:52 | 5 Value Stocks To Watch In The Healthcare Sector

2020-08-12 16:37:08 | Onconova Therapeutics: Q2 Earnings Insights

2020-08-12 16:05:00 | Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results

2020-08-07 08:00:00 | Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020

2020-08-04 08:00:00 | Onconova Therapeutics Announces Compliance with Nasdaq Bid Price Requirement

2020-08-03 11:52:03 | Onconova ONTX to Report Q2 Earnings: What's in the Offing?

2020-07-29 13:30:00 | Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis

2020-07-27 08:00:00 | Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease

2020-07-23 08:00:00 | Onconova Therapeutics Announces Publication of Preclinical Data Supporting Rigosertib’s Mechanism of Action as a Targeted Anticancer Therapy

2020-07-07 08:00:10 | Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS

2020-06-23 10:43:02 | Onconova Initiates Phase I/IIa Study on Lung Cancer Candidate

2020-06-23 08:00:10 | Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar

2020-06-22 08:00:10 | Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma

2020-06-12 08:00:10 | Onconova Therapeutics Announces Presentation at the 25th Congress of the European Hematology Association EHA

2020-06-08 08:00:10 | Onconova Therapeutics Announces Presentation at BIO Digital 2020

2020-05-28 09:44:06 | 3 “Strong Buy” Penny Stocks That Offer Massive Potential Gains